This article is more than 5 years old. Information may no longer be current.
VIDEO: ‘Practice-changing’ data show evidence of superiority of TAVR
Click Here to Manage Email Alerts
CHICAGO — In this video exclusive, Payam Dehghani, MD, interventional cardiologist at the University of Saskatchewan, Canada, highlights practice-changing data from the PARTNER 2 trial presented at the American College of Cardiology Scientific Session.
The PARTNER 2 trial included patients with severe aortic stenosis and intermediate risk for surgery who underwent transcatheter aortic valve replacement with a balloon-expandable system (Sapien XT, Edwards Lifesciences) or surgical AVR. Patients were also stratified into two cohorts based on clinical and imaging findings: a transfemoral-access cohort and a transthoracic-access cohort.
“We’ve been waiting for [these results] — that is, looking at [TAVR in] an intermediate-risk patient population. … When I think about intermediate [risk], I tend to think about a little lower risk, but … [in this study] the Society of Thoracic Surgeons [risk] score was about half of the STS score in the first PARTNER trial,” he said.
In this population, TAVR was noninferior to surgical AVR for the endpoint of death or disabling stroke. In addition, results showed that TAVR was associated with reduced risk for the primary outcome compared with surgery in the transfemoral-access cohort.
“The big take-home point for me … is that TAVR is going to replace therapy of aortic stenosis in this patient population,” Dehghani said.